SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that CNA Development LLC, an affiliate of Janssen Pharmaceuticals, Inc. (Janssen) has filed an…
SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the appointment of Christel Iffland, Ph.D. as a Vice President of Antibody Technologies…
SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with ONO PHARMACEUTICAL CO…
SAN DIEGO– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Menlo Park, CA-based TeneoBio, Inc. Under the license…
Ligand Enters OmniAb License Agreement with TeneoBio, Inc. Read More »
SAN DIEGO– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Gilead Sciences, Inc. Under the license, Gilead will be able…
Ligand Enters into OmniAb Platform License Agreement with Gilead Sciences Read More »
SAN DIEGO– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that two recent events relating to its OmniAb platform generated $4 million in combined payments due to Ligand…
Ligand Receives $4 Million from Expansion of Two OmniAb License Agreements Read More »
SAN DIEGO– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with ABBA Therapeutics AG, a Swiss biotechnology company…
Ligand Enters Into OmniAb Platform License Agreement With ABBA Therapeutics Read More »
SAN DIEGO– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Tizona Therapeutics, Inc., an immunology company developing…
Ligand Enters Into OmniAb Platform License Agreement with Tizona Therapeutics Read More »
SAN DIEGO– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Emergent BioSolutions Inc. (NYSE: EBS), a global specialty…
Ligand Enters Into OmniAb Platform License Agreement with Emergent BioSolutions Read More »
SAN DIEGO & PALO ALTO, Calif.– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and OMT, Inc. (Open Monoclonal Technology) announce the signing of agreements for Ligand to acquire OMT, Inc…
